Cargando…
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
BACKGROUND: We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. METHODS: We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage...
Autores principales: | Lindemann, Kristina, Malander, Susanne, Christensen, Rene D, Mirza, Mansoor R, Kristensen, Gunnar B, Aavall-Lundqvist, Elisabeth, Vergote, Ignace, Rosenberg, Per, Boman, Karin, Nordstrøm, Britta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924910/ https://www.ncbi.nlm.nih.gov/pubmed/24498853 http://dx.doi.org/10.1186/1471-2407-14-68 |
Ejemplares similares
-
Long‐term incidence of endometrial cancer after endometrial resection and ablation: A population based Swedish gynecologic cancer group (SweGCG) study
por: Flöter Rådestad, Angelique, et al.
Publicado: (2022) -
Modelling the Effect of Compliance with Nordic Nutrition Recommendations on Cardiovascular Disease and Cancer Mortality in the Nordic Countries
por: Saha, Sanjib, et al.
Publicado: (2019) -
Tru-Cut Biopsy in Gynecological Cancer: Adequacy, Accuracy, Safety and Clinical Applicability
por: Asp, Mihaela, et al.
Publicado: (2023) -
Leadership and well-being of employees in the Nordic countries: A literature review
por: Lundqvist, Daniel, et al.
Publicado: (2023) -
Endometrial aspiration cytology in gynecological disorders
por: Jadhav, Meenal V., et al.
Publicado: (2016)